Genpharmasec FY26 Net Profit Rises to ₹544.96 Lakh
Genpharmasec Limited reported a standalone net profit of ₹544.96 lakh for FY26, a significant rise from ₹280.04 lakh in the previous year, driven by a surge in revenue to ₹13,134.94 lakh. The consolidated net profit stood at ₹56.01 lakh. The Board approved the results on May 21, 2026, and the company published the audited financial results in newspapers on May 23, 2026.
*this image is generated using AI for illustrative purposes only.
Genpharmasec Limited has reported its audited standalone and consolidated financial results for the quarter and year ended March 31, 2026. The Board of Directors approved the results during a meeting held on May 21, 2026. The company published an extract of these results in newspapers Active Times and Mumbai Lakshadeep on May 23, 2026, pursuant to Regulation 30 and 47 of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.
For the financial year 2026, the company recorded a standalone net profit of ₹544.96 lakh, a significant increase from the ₹280.04 lakh reported in the previous year. Revenue from operations for the year surged to ₹13,134.94 lakh, up from ₹3,296.07 lakh in the prior year. For the quarter ended March 31, 2026, the company posted a net profit of ₹231.81 lakh on revenue of ₹5,166.42 lakh. The statutory auditors, M/s. Bilimoria Mehta & Co., issued an audit report with an unmodified opinion on the standalone and consolidated financial results.
Financial Performance
The company's total income for the year stood at ₹13,621.88 lakh, compared to ₹3,639.16 lakh in the previous year. Total expenses for the period were ₹12,978.19 lakh. Profit before tax for the year was ₹643.69 lakh, while the tax expense was recorded at ₹98.72 lakh.
| Metric | Year Ended March 31, 2026 (₹ Lakh) | Year Ended March 31, 2025 (₹ Lakh) |
|---|---|---|
| Revenue from Operations | 13,134.94 | 3,296.07 |
| Total Income | 13,621.88 | 3,639.16 |
| Total Expenses | 12,978.19 | 3,261.35 |
| Profit Before Tax | 643.69 | 377.81 |
| Net Profit | 544.96 | 280.04 |
Consolidated Results
On a consolidated basis, the company reported a net profit of ₹56.01 lakh for the year ended March 31, 2026, compared to ₹156.28 lakh in the previous year. Consolidated revenue from operations for the year was ₹13,993.77 lakh. The auditors noted material uncertainties regarding the going concern status of two subsidiaries, Derren Healthcare Private Limited and Clinigenome India Private Limited, due to losses and erosion of net worth. However, the financial statements were prepared on a going concern basis based on management plans and financial support from the holding company.
Board Decisions
Alongside the financial results, the Board approved the re-appointment of M/s. Abhishek M Agrawal & Co., Chartered Accountants, as the Internal Auditor of the company for the financial year 2026-27. The appointment is pursuant to Section 138 of the Companies Act, 2013. The Board also confirmed that the Statutory Auditors' report carries an unmodified opinion.
Historical Stock Returns for Genpharmasec
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| 0.0% | -7.81% | -3.28% | -20.27% | -44.86% | -79.04% |
What specific business segments or contracts drove Genpharmasec's nearly 4x revenue surge in FY2026, and are these growth drivers sustainable into FY2027?
What turnaround strategies does Genpharmasec's management plan to implement for subsidiaries Derren Healthcare and Clinigenome India to resolve their going concern uncertainties?
Given that consolidated net profit declined sharply to ₹56.01 lakh despite strong standalone performance, how will the financial drag from loss-making subsidiaries impact future capital allocation decisions?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
